Cargando…
2023年第3版《NCCN肿瘤临床实践指南:非小细胞肺癌》更新解读
Lung cancer is the malignant tumor with the highest morbidity and mortality in China. Non-small cell lung cancer (NSCLC) is the main pathological subtype of lung cancer. On April 13, 2023, the National Comprehensive Cancer Network (NCCN) released the third edition of the 2023 NCCN Oncology Clinical...
Autores principales: | ZHU, Lingling, WANG, Ting, WU, Juan, ZHAI, Xiaoqian, WU, Qiang, DENG, Hanyu, QIN, Changlong, TIAN, Long, ZHOU, Qinghua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial board of Chinese Journal of Lung Cancer
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365961/ https://www.ncbi.nlm.nih.gov/pubmed/37488078 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.18 |
Ejemplares similares
-
美国临床肿瘤学会Ⅳ期非小细胞肺癌化疗的临床实践指南更新
por: AZZOLI, Christopher G., et al.
Publicado: (2010) -
成人原发免疫性血小板减少症:2019版美国血液学会指南与国际共识报告更新解读
Publicado: (2020) -
2021年非小细胞肺癌重要临床研究纵观与解读
Publicado: (2022) -
2011年美国临床肿瘤学会年会——晚期非小细胞肺癌内科治疗进展
Publicado: (2011) -
成人原发免疫性血小板减少症研究与诊治国际共识报告更新(2019版)解读
Publicado: (2020)